SFSIG
JAZZ icon

San Francisco Sentry Investment Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

San Francisco Sentry Investment Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3
Closed – – 946
2019
Q1 		$0 Buy
+3
New +$391 ﹤0.01% 1000
2018
Q2 		– Sell
-29
Closed -$4K – 814
2018
Q1 		$4K Hold
29
– – ﹤0.01% 785
2017
Q4 		$4K Sell
29
-16
-36% -$2.22K ﹤0.01% 784
2017
Q3 		$7K Buy
+45
New +$6.8K ﹤0.01% 699

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

San Francisco Sentry Investment Group's JAZZ Position: Q2 2019 in Review

San Francisco Sentry Investment Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 3 shares.

San Francisco Sentry Investment Group first reported a position in JAZZ in Q3 2017 and held it in 4 quarters. The position peaked at $7K in Q3 2017. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • San Francisco Sentry Investment Group reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 3 Jazz Pharmaceuticals shares in Q2 2019.
  • San Francisco Sentry Investment Group first reported a position in Jazz Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • San Francisco Sentry Investment Group's Jazz Pharmaceuticals position peaked at $7K in Q3 2017.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2019, filed 8 Aug 2019.